SHANGHAI, China, May 14 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for first-quarter 2009.
(Logo:http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ) Highlights -- First-Quarter 2009 Net Revenues Increase 5% Year Over Year to $59.1 Million -- Laboratory Services Net Revenues Grow 33% Year Over Year to $56.5 Million, Driven by Organic Growth and the AppTec Acquisition -- China-Based Laboratory Services Net Revenues Grow 28% Year Over Year to $41.6 Million -- GAAP Diluted Earnings Per ADS of 16 Cents -- Non-GAAP Diluted Earnings Per ADS of 20 Cents -- Company Reconfirms 2009 Financial Guidance, Including 15-20% Net Revenue Growth in China-Based Laboratory Services
"WuXi PharmaTech got off to a good start in 2009 with solid first-quarter results," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "We achieved 33% year-over-year growth in Laboratory Services revenues, reflecting 28% growth in China-based Laboratory Services and the contribution of the AppTec acquisition on a year-over-year basis. Revenues in our U.S.-based Laboratory Services and China-based Manufacturing Services businesses were in line with our expectations and reflected the challenging operating environment. We remain on target to achieve our 2009 financial guidance, including 15-20% revenue growth in China-based Laboratory Services.
"We are expanding our platform of integrated services to help our customers advance their drug candidates as quickly and efficiently as possible. While our core discovery chemistry business continued its solid growth, we are seeing even stronger growth in newer capabilities such as discovery biology, DMPK (drug metabolism and pharmacokinetics)/ADME (absorption, distribution, metabolism, and excretion), process research, and bioanalytical services. We are pleased to have recently completed an FDA inspection of our bioanalytical testing laboratory in China without major observations for noncompliance issues.
"We are investing in an even broader suite of services to drive accelerated revenue growth in 2010 and beyond. We are planning capital expenditures of $50-60 million in 2009, the majority targeted for upgrading and expanding the facilities in our China-based Laboratory Services business to support the business growth. With the construction of a new facility in Jinshan, we have now expanded our manufacturing capability to commercial scale, with the aim of producing key ingredients for late-stage clinical trials and commercial supplies. We continue to invest in our Suzhou facility with the aim of becoming the leading China-based service provider in drug safety evaluation.
"Our mission as a company is to partner with the world's leading life science and medical device companies to help them improve the success of research and shorten the time of development," Dr. Li concluded.
First-quarter 2009 net revenues grew 5% year over year to $59.1 million, driven primarily by 28% growth in revenues for China-based Laboratory Services, offset by an 81% decline in Manufacturing Services revenues. China-based Laboratory Services benefited from strong demand year over year, as life science companies increasingly acted to reduce cost and improve productivity by outsourcing R&D services. Revenue in Manufacturing Services is inherently variable due to the size of this business. The year-over-year decline in Manufacturing Services revenue resulted from project delays that postponed work authorization and delivery. In addition, the majority of Manufacturing Services revenue in first-quarter 2008 came from a single non-recurring project. On a pro-forma basis, including January 2008 revenues of $5 million, U.S. testing revenues declined 1% in the quarter to $14.9 million on a year-over-year basis.
First-quarter 2009 GAAP gross profit declined 11% year over year to $23.3 million, mainly due to a decline in the gross-profit contribution of Manufacturing Services, offset by increased contribution from China-based Laboratory Services. First-quarter 2009 GAAP gross margin declined to 39% from 47% in the first quarter of 2008 due to declines in gross margin in China-based Laboratory Services, in the U.S. Laboratory Services business due to project mix, and in Manufacturing Services due to project mix and low capacity utilization.
Declines in first-quarter 2009 GAAP operating income and operating margin and in 2009 GAAP net income and net margin relative to the first quarter of 2008 reflect the same factors as those discussed above, as operating expenses, other income/expenses, and income taxes showed relatively little change year over year. Diluted earnings per ADS in the first quarter of 2009 were 16 cents compared to 19 cents in the first quarter of 2008. Mark-to-market foreign-exchange gains contributed 3.6 cents per share in first-quarter 2009 and 3.7 cents in first-quarter 2008.
Non-GAAP financial results exclude the impact of share-based compensation expenses, amortization and deferred tax impact of acquired intangible assets, and loss from discontinued operations.
First-quarter 2009 non-GAAP gross profit declined 10% year over year to $24.7 million, mainly due to a decline in the gross profit contribution of Manufacturing Services, offset by increased revenue from China-based Laboratory Services. First-quarter 2009 non-GAAP gross margin declined to 42% from 49% in the first quarter of 2008 due to declines in gross margin in China-based Laboratory Services, in the U.S. Laboratory Services business due to project mix, and in Manufacturing Services due to project mix and low capacity utilization. First-quarter 2009 non-GAAP gross margin increased by three percentage points to 42% compared to non-GAAP gross margin of 39% in the fourth quarter of 2008 due to cost-control efforts.
Declines in first-quarter 2009 non-GAAP operating income and operating margin and in 2009 non-GAAP net income and net margin relative to the first quarter of 2008 reflect the same factors as those discussed above, as operating expenses, other income/expenses, and income taxes showed relatively little change year over year. Non-GAAP diluted earnings per ADS were 20 cents compared to 25 cents in the first quarter of 2008. Mark-to-market foreign-exchange gains contributed 3.6 cents per share in first-quarter 2009 and 3.7 cents in first-quarter 2008.
(See the table titled "Reconciliation of GAAP to Non-GAAP" below). 2009 Financial Guidance The Company reconfirmed its earlier financial guidance for 2009: -- Total net revenues of $265 million-$275 million(1) -- Net revenue growth in China-based Laboratory Services of 15-20% compared to 2008 China-based Laboratory Services revenue -- Manufacturing Services net revenue lower than 2008 Manufacturing Services net revenue -- U.S. testing (AppTec) net revenue comparable to 2008 U.S. testing net revenue on a pro-forma basis(1) -- Non-GAAP gross profit and operating income lower than 2008 amounts in dollars and as percentages of net revenues as we invest in new capabilities and capacities -- Adjusted EBITDA (excluding share-based compensation charges and potential mark-to-market gains or losses from foreign-currency forward contracts) relatively flat with 2008 adjusted EBITDA of $72 million -- Capital expenditures of $50-$60 million (1) Our targeted net revenues of $265 million to $275 million in 2009 compare with $258.5 million in 2008 from our continuing operations on a pro-forma basis (non-GAAP). WuXi PharmaTech acquired AppTec, Inc. at the end of January 2008, and our reported results for AppTec in the first quarter of 2008 reflect two months of net revenues after the acquisition date. The pro-forma revenues include the January 2008 revenues from continuing operations of the AppTec business.
Commenting on financial performance and guidance, Edward Hu, chief operating officer and acting chief financial officer, said, "Our first-quarter 2009 financial results met our expectations and give us reason to reconfirm our full-year 2009 financial guidance. As anticipated, China-based Laboratory Services revenues grew strongly in the first quarter from continued growth in demand. Manufacturing Services revenues were very light in the quarter due to project delays. Revenue in this business is inherently variable. U.S. testing revenues were essentially flat relative to pro-forma first-quarter 2008 results due to weak economic conditions.
"We expect second-quarter 2009 revenues to grow 8-10% from first-quarter 2009 revenues. Manufacturing Services revenues should improve somewhat from the first quarter but remain very light in the second quarter ($4-5 million). Second-quarter total company gross profit margin is expected to be comparable to the first quarter."
WUXI PHARMATECH (CAYMAN) INC. UNAUDITED CONSOLIDATED BALANCE SHEETS (in thousands of U.S. Dollars, except ordinary share, ADS and par value data) March 31, December 31, 2009 2008 Assets: Current assets: Cash and cash equivalents 101,885 56,624 Restricted cash 2,696 1,338 Short-term investment -- 14,631 Accounts receivable, net 38,423 36,457 Inventories 7,526 6,926 Prepaid expenses and other current assets 9,592 7,281 Assets of discontinued operations (Note 1) 3,754 6,508 Total current assets 163,876 129,765 Non-current assets: Goodwill 23,956 23,956 Property, plant and equipment, net 159,742 152,704 Intangible assets, net 9,077 9,934 Prepaid land use rights 5,394 5,424 Deferred tax assets 9,026 8,807 Other non-current assets 5,792 5,809 Total non-current assets 212,987 206,634 Total assets 376,863 336,399 Liabilities and shareholders' equity: Current liabilities: Short-term and current portion of long-term debt 41,502 7,558 Accounts payable 17,538 19,829 Accrued expenses 9,250 14,279 Deferred revenue 3,825 3,373 Advanced subsidies 2,369 3,080 Other taxes payable 6,596 5,742 Other current liabilities 4,391 3,448 Liabilities of discontinued operations (Note 1) 196 1,495 Total current liabilities 85,667 58,804 Non-current liabilities: Long-term debt, excluding current portion 2,240 2,305 Advanced subsidies 1,782 1,819 Convertible notes 35,864 35,864 Other non-current liabilities 6,770 6,731 Total non-current liabilities 46,656 46,719 Total liabilities 132,323 105,523 Shareholders' equity: Ordinary shares ($0.02 par value, 5,002,550,000 authorized, 540,563,086 and 529,385,590 issued and outstanding as of March 31, 2009, and December 31, 2008, respectively) 10,811 10,588 Additional paid-in capital 326,655 324,629 Accumulated deficit (109,770) (121,505) Accumulated other comprehensive income 16,844 17,164 Total shareholders' equity 244,540 230,876 Total liabilities and shareholders' equity 376,863 336,399 Note 1: The biologics manufacturing operations in Philadelphia, which management decided to close in December 2008, were classified as discontinued operations. WUXI PHARMATECH (CAYMAN) INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands of U.S. dollars, except ADS data and per ADS data) Three Months Ended March 31, 2009 2008 % (Note 3) Change Net revenues: Laboratory Services (Note 2) 56,596 42,515 33% Manufacturing Services 2,552 13,652 (81%) Total net revenues 59,148 56,167 5% Cost of revenues: Laboratory Services (Note 2) (33,856) (22,603) 50% Manufacturing Services (1,973) (7,367) (73%) Total cost of revenues (35,829) (29,970) 20% Gross profit: Laboratory Services (Note 2) 22,740 19,912 14% Manufacturing Services 579 6,285 (91%) Total gross profit 23,319 26,197 (11%) Operating expenses: Selling and marketing expenses (1,334) (1,354) (1%) General and administrative expenses (11,710) (11,137) 5% Total operating expenses (13,044) (12,491) 4% Operating income 10,275 13,706 (25%) Other income (expenses), net: Other income (expenses), net 3,393 2,807 21% Interest income (expenses), net (50) 516 (110%) Total other income (expenses), net 3,343 3,323 1% Income from continuing operations before income taxes 13,618 17,029 (20%) Income tax expenses (1,883) (1,861) 1% Income from continuing operations 11,735 15,168 (23%) Loss on discontinued operations, net (Note 1) Loss from operations of discontinued component -- (2,044) * Income tax benefit -- 737 * Loss on discontinued operations -- (1,307) * Net income 11,735 13,861 (15%) Basic net earnings (loss) per ADS: Earnings from continuing operations 0.18 0.25 (29%) Loss on discontinued operations-net of tax (Note 1) -- (0.03) * Net earnings per ADS 0.18 0.22 (22%) Weighted average ADS outstanding-basic 67,013,222 61,895,469 Diluted net earnings (loss) per ADS: Earnings from continuing operations 0.16 0.21 (23%) Loss on discontinued operations-net of tax (Note 1) -- (0.02) * Net earnings per ADS 0.16 0.19 (16%) Weighted average ADS outstanding-diluted 72,700,738 72,416,243 * Not meaningful Note 2: First-quarter 2009 net revenues for Laboratory Services were comprised of $41.6 million for China-based Laboratory Services and $14.9 million for U.S. testing. The first-quarter 2008 amount was comprised of $32.4 million for China-based Laboratory Services and $10.1 million for U.S. testing. Note 3: Financial results of AppTec were consolidated as of January 31, 2008. WUXI PHARMATECH (CAYMAN) INC. RECONCILIATION OF GAAP TO Non-GAAP (in thousands of U.S. Dollars, except ADS data and par value data) Three Months Ended March 31, 2009 2008 % GAAP gross profit 23,319 26,197 (11%) GAAP gross margin 39% 47% Adjustments Share-based compensation 591 699 Amortization of acquired intangible assets 764 384 Non-GAAP gross profit 24,674 27,280 (10%) Non-GAAP gross margin 42% 49% GAAP operating income 10,275 13,706 (25%) GAAP operating margin 17% 24% Adjustments Share-based compensation 1,999 2,978 Amortization of acquired intangible assets 764 384 Non-GAAP operating income 13,038 17,068 (24%) Non-GAAP operating margin 22% 30% GAAP net income 11,735 13,861 (15%) GAAP net margin 20% 25% Adjustments: Share-based compensation 1,999 2,978 Amortization of acquired intangible assets 764 384 Deferred tax impact related to acquired intangible assets (296) (151) Loss from discontinued operations -- 1,307 Non-GAAP net income 14,202 18,379 (23%) Non-GAAP net margin 24% 33% GAAP net income 11,735 13,861 (15%) Add back: Depreciation and amortization 5,007 4,855 Interest (income) expenses, net 50 (516) Income tax expenses 1,883 1,124 EBITDA 18,675 19,324 (3%) Adjustments Share-based compensation 1,999 2,978 Mark-to-market gain from foreign-currency forward contracts (2,621) (2,683) Adjusted EBITDA 18,053 19,619 (8%) Income attributable to holders of ADS (Non-GAAP): Basic 14,202 18,379 (23%) Diluted 14,202 18,379 (23%) Basic earnings per ADS (Non-GAAP) 0.21 0.30 (29%) Diluted earnings per ADS (Non-GAAP) 0.20 0.25 (23%) Weighted average ADS outstanding - basic (Non-GAAP) 67,013,222 61,895,469 Weighted average ADS outstanding - diluted (Non-GAAP) 72,700,738 72,416,243 WUXI PHARMATECH (CAYMAN) INC. REVENUE RECONCILIATION BY GEOGRAPHY (in thousands of U.S. Dollars) Three Months Ended March 31, 2009 2008 % Net revenues: China-based Laboratory Services 41,648 32,418 28% China-based Manufacturing Services 2,552 13,652 (81%) Subtotal 44,200 46,070 (4%) U.S.-based Laboratory Services 14,948 10,097 48% Total net revenues 59,148 56,167 5%
WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Friday, May 15, 2009, to discuss its first-quarter 2009 financial results and future prospects. The conference call may be accessed by calling:
United States: 1-866-519-4004 China (Landline): 800-819-0121 China (Mobile): 400-620-8038 Hong Kong: 800-933-053 United Kingdom: 0-808-234-6646 International: +65-6735-7955 Conference ID: 96870349 Web PIN: 8656
A telephone replay will be available two hours after the call's completion at:
United States: 1-866-214-5335 China North: 10-800-714-0386 China South: 10-800-140-0386 Hong Kong: 800-901-596 United Kingdom: 0-800-731-7846 International: +61-2-8235-5000 Passcode: 96870349
A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxiapptec.com .
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .
Use of Non-GAAP and Pro-Forma Financial Measures
We have provided first-quarter 2008 and 2009 gross profit, operating income, net income and earnings per ADS on a non-GAAP basis, which excludes share-based compensation expenses, amortization and deferred tax impact of acquired intangible assets, and discontinued operations. The pro-forma first- quarter 2008 revenues include the January 2008 revenues from continuing operations of the AppTec business. We believe both management and investors benefit from referring to these non-GAAP and pro-forma financial measures in assessing our financial performance and liquidity and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends. We expect to continue providing gross profit, operating income, and net income on a non-GAAP basis using a consistent method on a quarterly basis.
You should not view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of non-GAAP measures to GAAP measures for the indicated periods attached hereto.
Cautionary Note Regarding Forward-Looking Statements
Statements in this release contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995, including, among others, expected 2009 operating results (including estimated total net revenue, China- based Laboratory Services and U.S. testing net revenues and related adjusted EBITDA and other trends), planned capital expenditure and investment levels, and the anticipated benefits of those efforts and the planned expansion of our service offerings and areas of related revenue growth.
These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Among other factors, continued uncertainty in the global economy and the pressures being felt by our customers and pharmaceutical industry consolidation may adversely impact our business and the trends for outsourced R&D and manufacturing for longer than expected or more severely than expected; we may be unable to successfully make our planned investments and capital expenditures on a timely basis, these investments may not yield the desired results, and we may need to modify the nature and level of our investments and capital expenditures; pharmaceutical companies may not change their business models as expected or in a manner favorable to us; we may fail to capitalize on the opportunities presented; we may not maintain our preferred provider status with our clients; and may be unable to successfully expand our capabilities to meet client needs. In addition, other factors that could cause our actual results to differ from what we currently anticipate include our limited operating history; failure to generate sufficient future cash flows or secure any required future financing on acceptable terms or at all; failure to retain key personnel; effective integration of continuing products and services from AppTec; our reliance on a limited number of customers to continue to account for a high percentage of our revenues; risk of payment failure by any of our large customers, which could significantly harm our cash flows and profitability; dependence upon the continued service of our senior management and key scientific personnel, and our ability to retain our existing customers or expand our customer base. You should read the financial information contained in this release in conjunction with the consolidated and pro-forma financial statements and related notes thereto included in our 2007 Annual Report on Form 20-F filed with and available on the Securities and Exchange Commission's website at http://www.sec.gov . For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 10 of our 2007 Annual Report on Form 20-F. Our results of operations for the first-quarter 2009 are not necessarily indicative of our operating results for any future periods. All projections in this release are based on limited information currently available to us, which is subject to change. Although these projections and the factors influencing them will likely change, we undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law. Such information speaks only as of the date of this release.
For more information, please contact: WuXi PharmaTech (Cayman) Inc. Ronald Aldridge (for investors) Director of Investor Relations Tel: +1-215-218-5515 Email: firstname.lastname@example.org Stephanie Liu (for the media) Tel: +86-21-5046-4362 Email: email@example.com
|SOURCE WuXi PharmaTech (Cayman) Inc.|
Copyright©2009 PR Newswire.
All rights reserved